Tyra Biosciences Reports Increased R&D Investment in Q1 2025

Tyra Bioscience, Inc ( (TYRA) ) has released its Q1 earnings. Here is a breakdown of the information Tyra Bioscience, Inc presented to its investors.

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology, with a unique in-house precision medicine platform called SNÅP. The company aims to address large opportunities in targeted oncology and genetically defined conditions.

In its latest earnings report, Tyra Biosciences highlighted a significant increase in operating expenses, particularly in research and development, which rose to $24.96 million for the first quarter of 2025, up from $17.20 million in the same period of 2024. The company reported a net loss of $28.15 million for the quarter, compared to $18.19 million in the previous year, reflecting its ongoing investment in advancing its drug development pipeline.

Key financial metrics showed that Tyra Biosciences ended the quarter with $100.72 million in cash and cash equivalents, and $218.22 million in marketable securities, indicating a strong liquidity position to support its research initiatives. The company also reported an increase in additional paid-in capital, reaching $602.30 million, up from $593.69 million at the end of 2024, driven by stock-based compensation and the issuance of common stock under benefit plans.

Looking ahead, Tyra Biosciences remains focused on advancing its clinical-stage programs, including TYRA-300, TYRA-200, and TYRA-430, which are designed to overcome the limitations of first-generation FGFR inhibitors. The management is optimistic about the potential of its SNÅP platform to deliver next-generation precision medicines, positioning the company for future growth in the biotechnology sector.